BioCryst Eyes $1B Rare-Disease Future Through External Innovation

BioCryst is pivoting to external innovation, using cash flow to license or acquire earlier-stage rare-disease programs while maintaining profitability.

Management targets more than $1 billion in revenue by 2030 from ORLADEYO, navenibart and potentially a third product.

ORLADEYO remains the company’s foundation, with continued patient growth, expansion into pediatric HAE and opportunities among patients with normal C1 inhibitor levels.

BioCryst expects competition from Pharvaris to affect some new patient starts but believes existing ORLADEYO users are less likely to switch.

BioCryst’s key pipeline catalysts include a third-quarter readout for navenibart’s pivotal ALPHA-ORBIT trial and year-end data for BCX17725 in Netherton syndrome.

Navenibart is intended to offer quarterly or semiannual dosing for patients currently using injectable HAE prophylaxis.

BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event.

Gayer, who became CEO on Jan. 1, said the company has moved away from internal drug discovery following its transition to profitability. Instead, BioCryst plans to use its growing cash flow to acquire or license medicines that can support a broader rare-disease portfolio.

“We think the best way to go forward is through external innovation,” Gayer said. He outlined a longer-term goal of having ORLADEYO, navenibart and potentially a third product on the market by the end of 2030, generating more than $1 billion in revenue while maintaining a stable cost base and increasing profitability.

Gayer said BioCryst’s decision to discontinue internal discovery capabilities was driven by the opportunity to evaluate a broader universe of rare-disease programs rather than funding a limited number of internal projects. The company has added scientific leadership, including Chief R&D Officer Dr. Sandeep Menon and Chief Scientific Officer David Jenkins, to evaluate outside opportunities.

The company’s acquisition of Astria Therapeutics and its navenibart candidate was an example of the strategy, though Gayer said future transactions are more likely to involve earlier-stage Phase I or Phase II assets than similarly sized acquisitions.

BioCryst paid an enterprise value of approximately $700 million for Astria, according to Gayer. Going forward, he said the company expects potential licensing transactions in the range of $100 million to $200 million upfront, with additional payments structured later. He said BioCryst does not intend to strain its balance sheet and will maintain profitability.

The company is focused on rare diseases requiring chronic, self-administered or home-administered therapies. Gayer said BioCryst does not plan to pursue oncology, hospital-delivered products, gene therapy or cell therapy.

Gayer said ORLADEYO remains the foundation of BioCryst’s business and has continued to add patients more than five years after launch.

ORLADEYO is the only oral prophylactic treatment in the HAE market, he said, and its growth has been supported by physician experience, real-world evidence and BioCryst’s patient-access efforts.

He said approximately 60% of patients who begin ORLADEYO remain on treatment for one year, reflecting what he described as strong efficacy for a majority of patients. Gayer noted that the medicine is not appropriate for every patient.